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Discussion {#onco12708-sec-0008}
==========

To the best of our knowledge, this is the first prospective study to demonstrate the safety of a shortened infusion of ramucirumab. We aimed to evaluate the safety of a short‐term infusion of ramucirumab. Our study met its primary endpoint, demonstrating that IRR rate during the first short‐term infusion was 0% (95% CI, 0%--0.72%). Additionally, among a total of 149 short‐term infusions, no IRR was observed. The frequency of ramucirumab‐related adverse events was consistent with that in previous reports, and no unexpected adverse events related to the study treatment were observed. These results demonstrated that a short‐term infusion of ramucirumab was safe. This can allow patients, particularly outpatients, to conveniently receive chemotherapy and reduce medical staff workload. We strongly believe our findings will be beneficial to both patients and medical staff.

###### Results of a short‐term infusion of ramucirumab (*n* = 40)
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Trial Information {#onco12708-sec-0009}
=================

DiseaseAdvanced cancer/solid tumor onlyStage of Disease/TreatmentMetastatic/advancedPrior TherapyNo designated number of regimensType of Study ‐ 1Phase IIType of Study ‐ 2Single armPrimary EndpointSafetySecondary EndpointSafetySecondary EndpointToxicityAdditional Details of Endpoints or Study DesignEligibility criteria included the following: (a) histologically proven gastrointestinal cancer; (b) first ramucirumab infusion administered over 60 minutes without development of an IRR; (c) no severe respiratory or cardiovascular comorbidities; and (d) no history of allergy or IRR to other chemotherapeutic agents. Our study was designed to have a maximum IRR rate of 15%, with α and β errors of .05 and .20, respectively, considering that the minimum sample size was 40 patients.Investigator\'s AnalysisShortened infusion of ramucirumab is a safe and feasible method.

Drug Information {#onco12708-sec-0010}
================

Drug 1 Generic/Working NameRamucirumabTrade NameCyramzaCompany NameEli LillyDrug TypeAntibodyDrug ClassVascular endothelial glistItemPairth factor receptor (VEGFR)Dose8 milligrams (mg) per kilogram (kg)RouteIVSchedule of AdministrationIntravenous administration of ramucirumab over 20 minutes every 2 weeks in combination with paclitaxel, nanoparticle albumin‐bound paclitaxel, irinotecan with fluorouracil and leucovorin (FOLFIRI), or irinotecan.

Patient Characteristics {#onco12708-sec-0011}
=======================

Number of Patients, Male22Number of Patients, Female18StageOnly metastatic or advanced; stage IV: 40 (100%)AgeMedian (range): 68.5 (32--85)Number of Prior Systemic TherapiesMedian (range): 1 (1--2)Performance Status: ECOG0 --- 161 --- 232 --- 13 --- 0Cancer Types or Histologic SubtypesGastric cancer, 27; colorectal cancer, 13

Primary Assessment Method {#onco12708-sec-0012}
=========================

Number of Patients Screened42Number of Patients Enrolled40Number of Patients Evaluable for Toxicity40Evaluation MethodCommon Terminology Criteria for Adverse Events (CTCAE) version 4.0

Adverse Events {#onco12708-sec-0013}
==============

imageJohn Wiley & Sons, Ltd.[^1]

Assessment, Analysis, and Discussion {#onco12708-sec-0014}
====================================

CompletionStudy completedInvestigator\'s AssessmentShortened infusion of ramucirumab is a safe and feasible method.

 {#onco12708-sec-1315}

Ramucirumab is a fully human immunoglobulin G monoclonal antibody against vascular endothelial growth factor receptor‐2 (VEGFR‐2), a receptor for VEGF‐A, VEGF‐C, and VEGF‐D \[[1](#onco12708-bib-0001){ref-type="ref"}\]. Ramucirumab has been shown to be effective in several cancer types, including gastric, colorectal, and non‐small cell lung cancer \[[2](#onco12708-bib-0002){ref-type="ref"}\], \[[3](#onco12708-bib-0003){ref-type="ref"}\], \[[4](#onco12708-bib-0004){ref-type="ref"}\], \[[5](#onco12708-bib-0005){ref-type="ref"}\]. In general, although antibody therapies are less toxic compared with cytotoxic agents, they have peculiar toxicity profiles. A typical adverse event is infusion‐related reaction (IRR), The symptoms of IRR include fever, chills, headache, pruritus, rash, cough, collapse, angioedema, and, in rare cases, life‐threating events such as respiratory disturbance or circulatory failure. Its mechanism is considered to be different from IgE‐mediated hypersensitivity due to type 1 allergic reaction \[[6](#onco12708-bib-0006){ref-type="ref"}\]. Because infusion duration of antibody therapies may affect IRR occurrence, monoclonal antibodies are gradually administered. Ramucirumab has been administered for over 60 minutes, but no robust evidence supports this duration. Ramucirumab is a fully human protein, and IRR occurrence due to its use has been reported to be markedly low (0.4%--5.8%) \[[2](#onco12708-bib-0002){ref-type="ref"}\], \[[3](#onco12708-bib-0003){ref-type="ref"}\]. Several studies have shown that rapid infusion of other antibodies was safe. Salar et al. reported rapid administration of rituximab, which is more closely associated with IRR, and proposed that a 90‐minute infusion schedule was well tolerated and safe \[[7](#onco12708-bib-0007){ref-type="ref"}\]. Sehn et al. also examined that a 90‐minute rituximab administration for more than 1,200 cases and reported that no grade 3 or 4 infusion reactions were observed \[[8](#onco12708-bib-0008){ref-type="ref"}\]. As for bevacizumab, trastuzumab, and panitumumab, similar studies have been performed and indicated that it is possible to shorten infusion time \[[9](#onco12708-bib-0009){ref-type="ref"}\], \[[10](#onco12708-bib-0010){ref-type="ref"}\], \[[11](#onco12708-bib-0011){ref-type="ref"}\], \[[12](#onco12708-bib-0012){ref-type="ref"}\]. Therefore, we hypothesized that it is possible to shorten the infusion duration of ramucirumab for patients without IRR during the first administration.

The primary endpoint, IRR rate during the first short‐term infusion, was 0% (95% confidence interval, 0%--0.72%). Additionally, among the 149 short‐term infusions, no IRR was observed. In total, 13 patients (32.5%) developed adverse events related to ramucirumab. One (2.5%) and two (5.0%) patients developed grade 3 upper gastrointestinal hemorrhage and proteinuria, respectively. The incidence of these adverse events was consistent with that in previous reports. Therefore, our findings demonstrated that a short‐term infusion of ramucirumab was safe. In cases with no IRR upon the first administration of ramucirumab over 60 minutes, a shorter 20‐minute infusion can be used for the subsequent administrations. When ramucirumab is administered in combination with other cytotoxic drugs, it requires considerable time, increasing the burden on patients and medical staff. A shorter infusion can be beneficial to patients and medical staff.

There were a few limitations to the present study. First, data on pharmacokinetics of ramucirumab were not obtained. However, in a previous report, shortening the infusion duration did not affect the blood concentration of panitumumab \[[12](#onco12708-bib-0012){ref-type="ref"}\], another fully human antibody. Second, this study included patients with differing treatment regimens, resulting in differences in terms of premedication. Our results should be validated in a larger sample sufficiently representing each regimen; however, this is the first study demonstrating that a 20‐minute ramucirumab infusion is safe and feasible for patients with gastrointestinal cancer despite these limitations. The shortened infusion time can reduce the burden of both patients and medical staff. Further studies are warranted to confirm the safety of short‐term ramucirumab infusion.

**UMIN Clinical Trial Registry:** [UMIN000029318](https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000031511)

**Sponsor(s):** Aichi Cancer Research Foundation

**Principal Investigators:** Seiichiro Mitani, Naoya Hashimoto

**IRB Approved:** Yes

[Click here to access other published clinical trials](http://theoncologist.alphamedpress.org/cgi/collection/clinical-trial-results).
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[^1]: Abbreviation: NC/NA, no change from baseline/no adverse event.
